Expression of TGF-β Superfamily Receptor ALK-5 Is Associated with Decreased Overall Survival of AML Patients Receiving Standard AML Chemotherapy

被引：0
|
作者：
Otten, Jasmin [1 ,6 ]
Schmitz, Lisa [1 ,6 ]
Vettorazzi, Eik [2 ]
Schultze, Alexander [1 ,6 ]
Krauter, Juergen [3 ]
Bokerneyer, Carsten [1 ,6 ]
Fiedler, Walter [4 ,5 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Univ, Ctr Canc, Dept Oncol Hematol,Sect Bone Marrow Transplantat, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidmiol, Hamburg, Germany
[3] Hannover Med Sch, Dept Hematol Hemostaseol Oncol & Stem Cell Transp, D-3000 Hannover, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Univ, Ctr Canc, Dept Hematol & Oncol,Sect Pneumol, Hamburg, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Univ, Ctr Canc, Dept Hematol & Oncol,Sect Bone Marrow Transplanta, Hamburg, Germany
[6] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Univ, Ctr Canc, Dept Oncol Hematol,Sect Pneumol, Hamburg, Germany
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：641 / 641
页数：1
相关论文
共 14 条
  • [1] Expression of TGF-β receptor ALK-5 has a negative impact on overall survival of patients with Acute Myeloid Leukemia
    Otten, J.
    Schmitz, L.
    Vettorazzi, E.
    Schultze, A.
    Krauter, J.
    Loges, S.
    Bokemeyer, C.
    Fiedler, W.
    ONKOLOGIE, 2010, 33 : 233 - 233
  • [2] RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
    Ball, Brian J.
    Hsu, Meier
    Devlin, Sean M.
    Famulare, Christopher
    Cai, Sheng F.
    Dunbar, Andrew
    Epstein-Peterson, Zachary D.
    Menghrajani, Kamal
    Glass, Jacob L.
    Taylor, Justin
    Viny, Aaron D.
    Goldberg, Aaron D.
    Tallman, Martin S.
    Stein, Eytan M.
    BLOOD, 2019, 134
  • [3] Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia
    Otten, J.
    Schmitz, L.
    Vettorazzi, E.
    Schultze, A.
    Marx, A. H.
    Simon, R.
    Krauter, J.
    Loges, S.
    Sauter, G.
    Bokemeyer, C.
    Fiedler, W.
    LEUKEMIA, 2011, 25 (02) : 375 - +
  • [4] Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia
    J Otten
    L Schmitz
    E Vettorazzi
    A Schultze
    A H Marx
    R Simon
    J Krauter
    S Loges
    G Sauter
    C Bokemeyer
    W Fiedler
    Leukemia, 2011, 25 : 375 - 379
  • [5] DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapy
    Tschanter, P.
    Krug, U.
    Fueller, M.
    Klein, M.
    Goellner, S.
    Rohde, C.
    Roellig, C.
    Thiede, C.
    Lilly, M. A.
    Haack, B.
    Koschmieder, A.
    Stelljes, M.
    Dugas, M.
    Koschmieder, S.
    Gerss, J.
    Butterfass-Bahloul, T.
    Wagner, R.
    Eveslage, M.
    Thiem, U.
    Krause, S. W.
    Kaiser, U.
    Kunzmann, V
    Steffen, B.
    Noppeney, R.
    Herr, W.
    Baldus, C. D.
    Schmitz, N.
    Goetze, K.
    Reichle, A.
    Kaufmann, M.
    Neubauer, A.
    Schaefer-Eckart, K.
    Haenel, M.
    Peceny, R.
    Frickhofen, N.
    Kiehl, M.
    Giagounidis, A.
    Goerner, M.
    Repp, R.
    Link, H.
    Kiani, A.
    Naumann, R.
    Bruemmendorf, T. H.
    Serve, H.
    Ehninger, G.
    Berdel, W. E.
    Mueller-Tidow, C.
    Oncology Research and Treatment, 2015, 38 : 122 - 122
  • [6] WT1 Expression Is Associated with Poor Overall Survival after Azacytidine and DLI in a Cohort of Adult AML and MDS Patients
    Aydin, Semra
    Schmitz, Jennifer
    Dellacasa, Chiara M.
    Dogliotti, Irene
    Giaccone, Luisa
    Busca, Alessandro
    CANCERS, 2024, 16 (17)
  • [7] Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation
    Altman, Jessica K.
    Luger, Selina M.
    Frankfurt, Olga
    Zuckerman, Tsila
    Koprivnikar, Jamie L.
    Kota, Vamsi
    Emadi, Ashkan
    Bhatnagar, Bhavana
    Bixby, Dale L.
    Burch, Micah M.
    Wolach, Ofir
    Levi, Itai
    Gourevitch, Anna
    Ram, Ron
    Flaishon, Liat
    Tessler, Shoshi
    Gengrinovitch, Stela
    Ben Yakar, Ruth
    Rowe, Jacob M.
    BLOOD, 2020, 136
  • [8] Early Clearance of Peripheral Blood Blasts but Not White Blood Cells Is a Powerful Prognostic marker for complete Response and Overall Survival in Patients with Acute Myeloid Leukemia (AML) receiving Induction Chemotherapy
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Brandt, Mark
    Pierce, Sherry
    Borthakur, Gautam
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 675 - 675
  • [9] Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Allan, John N.
    Roboz, Gail J.
    Feldman, Eric J.
    Scandura, Joseph M.
    Ritchie, Ellen K.
    Lam, Linda
    Xie, Wen
    Hsu, Hsiao-Ting
    Hassane, Duane C.
    Guzman, Monica L.
    BLOOD, 2014, 124 (21)
  • [10] CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML)
    Jiang, Yongfang
    Xu, Ping
    Yao, Dandan
    Chen, Xi
    Dai, Haibin
    MEDICAL SCIENCE MONITOR, 2017, 23 : 1725 - 1732
12